Given the low cost of coronary artery calcium (CAC) testing and the high likelihood that it will change management of the patient, the cost-effectiveness of CAC testing is robust due to better and more accurate targeting of intermediate risk patients to statin and aspirin therapy and promotion of adherence to those therapies. In this interview, Matthew Budoff, MD; C. Noel Bairey Merz, MD, FACC; and Poonam Velagapudi, MD, MS, discuss the cost-effectiveness of CAC testing and statin therapy.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Acute Coronary Syndromes, Dyslipidemia, Prevention, Nonstatins, Novel Agents, Statins

Keywords: ACCELLite, Primary Prevention, Acute Coronary Syndrome, Medication Adherence, Calcium, Aspirin, Cost-Benefit Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors

< Back to Listings